Piper Sandler Remains a Hold on Supernus Pharmaceuticals (SUPN)
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $44
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q1 2025 Earnings Conference
Supernus Projects $600M-$630M Revenue for 2025 With Robust Growth in Core Products
Optimistic Growth Prospects for Supernus Pharmaceuticals Driven by Qelbree's Market Potential
SUPERNUS PHARMACEUTICALS Earnings Results: $SUPN Reports Quarterly Earnings
Express News | Supernus Pharmaceuticals Affirms FY2025 Sales Guidance of $600.00M-$630.00M Vs $624.69M Est
Supernus Pharmaceuticals | 10-Q: Quarterly report
Supernus Pharmaceuticals Reports 44% Increase in Qelbree Sales and Launches ONAPGO in Q1 2025
Earnings Flash (SUPN) Supernus Pharmaceuticals Reports Q1 Revenue $149.8M, Vs. FactSet Est of $147.9M
Supernus Pharmaceuticals | 8-K: Supernus Announces First Quarter 2025 Financial Results
Supernus Pharmaceuticals GAAP EPS of -$0.21 Misses by $0.24, Revenue of $149.9M Beats by $1.96M
Express News | Supernus Pharmaceuticals Q1 Adjusted Operating Earnings USD 25.9 Million Vs. IBES Estimate USD 24.1 Million
Express News | Supernus Pharmaceuticals Q1 Product Sales USD 142 Million
Express News | Supernus Pharmaceuticals Q1 Operating Earnings USD -10.256 Million
Express News | Supernus Pharmaceuticals Q1 Adjusted Revenue USD 126.8 Million Vs. IBES Estimate USD 146.9 Million
Supernus Pharmaceuticals 1Q Loss $11.8M >SUPN
Earnings Scheduled For May 6, 2025
Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview
Earnings Preview: SUPN to Report Financial Results Post-market on May 06